191 related articles for article (PubMed ID: 36873185)
1. Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in
Feng Y; Han Y; Hu A; Qu Y; Hu Y; Wu H; Wang X; He L
Acta Pharm Sin B; 2023 Feb; 13(2):598-617. PubMed ID: 36873185
[TBL] [Abstract][Full Text] [Related]
2. Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia.
Han Y; Hu A; Qu Y; Xu Q; Wang H; Feng Y; Hu Y; He L; Wu H; Wang X
Pharmacol Res; 2023 Mar; 189():106700. PubMed ID: 36796466
[TBL] [Abstract][Full Text] [Related]
3. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
Shi Y; Xue Y; Wang C; Yu L
Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
[TBL] [Abstract][Full Text] [Related]
4. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
5. Nucleophosmin gene mutations in acute myeloid leukemia.
Chen W; Rassidakis GZ; Medeiros LJ
Arch Pathol Lab Med; 2006 Nov; 130(11):1687-92. PubMed ID: 17076533
[TBL] [Abstract][Full Text] [Related]
6. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
[TBL] [Abstract][Full Text] [Related]
7. When the good go bad: Mutant NPM1 in acute myeloid leukemia.
Kunchala P; Kuravi S; Jensen R; McGuirk J; Balusu R
Blood Rev; 2018 May; 32(3):167-183. PubMed ID: 29157973
[TBL] [Abstract][Full Text] [Related]
8. N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.
De Cola A; Franceschini M; Di Matteo A; Colotti G; Celani R; Clemente E; Ippoliti R; Cimini AM; Dhez AC; Vallée B; Raineri F; Cascone I; Destouches D; De Laurenzi V; Courty J; Federici L
Cancer Lett; 2018 Jan; 412():272-282. PubMed ID: 29111347
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
[TBL] [Abstract][Full Text] [Related]
10. EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.
Skayneh H; Jishi B; Hleihel R; Hamie M; El Hajj R; Deleuze-Masquefa C; Bonnet PA; El Sabban M; El Hajj H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408798
[TBL] [Abstract][Full Text] [Related]
11. Nucleophosmin 1 Mutations in Acute Myeloid Leukemia.
Zarka J; Short NJ; Kanagal-Shamanna R; Issa GC
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32545659
[TBL] [Abstract][Full Text] [Related]
12. Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML.
Gionfriddo I; Brunetti L; Mezzasoma F; Milano F; Cardinali V; Ranieri R; Venanzi A; Pierangeli S; Vetro C; Spinozzi G; Dorillo E; Wu HC; Berthier C; Ciurnelli R; Griffin MJ; Jennings CE; Tiacci E; Sportoletti P; Falzetti F; de Thé H; Veal GJ; Martelli MP; Falini B
Leukemia; 2021 Sep; 35(9):2552-2562. PubMed ID: 33654209
[TBL] [Abstract][Full Text] [Related]
13. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
14. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
15. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.
Jin H; Yang L; Wang L; Yang Z; Zhan Q; Tao Y; Zou Q; Tang Y; Xian J; Zhang S; Jing Y; Zhang L
J Exp Clin Cancer Res; 2018 Jan; 37(1):8. PubMed ID: 29343273
[TBL] [Abstract][Full Text] [Related]
16. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
[TBL] [Abstract][Full Text] [Related]
17. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.
Du Pisani LA; Shires K
Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):106-14. PubMed ID: 26183674
[TBL] [Abstract][Full Text] [Related]
18. The Role of Nucleophosmin 1 (
Kelemen K
Life (Basel); 2022 Jan; 12(1):. PubMed ID: 35054502
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
[TBL] [Abstract][Full Text] [Related]
20. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.
El Hussein S; DiNardo CD; Takahashi K; Khoury JD; Fang H; Furudate K; Lyapichev KA; Garces S; Kanagal-Shamanna R; Ok CY; Patel KP; Routbort MJ; Ravandi F; Medeiros LJ; Wang SA; Loghavi S
Bone Marrow Transplant; 2022 Mar; 57(3):370-376. PubMed ID: 34992253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
